November 7, 2017 / 1:43 PM / a month ago

BRIEF-Krystal Biotech says KB103 granted orphan drug designation by FDA

Nov 7 (Reuters) - Krystal Biotech Inc

* Krystal Biotech’s KB103 granted orphan drug designation by the FDA to treat patients with dystrophic epidermolysis bullosa

* Krystal Biotech Inc - on track to file IND for KB103 in Q1 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below